BRCA Mutation
Understand BRCA mutation diagnosis, including BRCA1 and BRCA2 gene mutations, and breast cancer susceptibility gene testing. Learn about clinical documentation and medical coding for BRCA mutations, relevant healthcare guidelines, and genetic testing implications for patient care. This resource provides information on BRCA mutation diagnosis, breast cancer risk assessment, and hereditary cancer syndromes.
Inherited gene changes (BRCA1/2) that increase breast, ovarian, and other cancer risks.
Often no early signs, but family history of these cancers is a strong indicator.
Genetic counseling, oncology clinics, primary care for risk assessment and screening.
ICD-10 Code Families
Complete code families applicable to Z15.01
When to use each related code
| Description | When to use |
|---|---|
| Increased risk of breast, ovarian, and other cancers. | Use for confirmed BRCA1 or BRCA2 mutations. Code specific gene if known. |
| Family history of breast/ovarian cancer, increased risk but no identified mutation. | Use when patient has strong family history suggestive of BRCA but genetic testing is negative or unavailable. |
| Genetic predisposition to several cancers, including breast and ovarian. | Use for hereditary breast and ovarian cancer syndrome (HBOC) when BRCA status is unknown or other genes are involved. |
Best-practice checklist
- ✓BRCA1/2 genetic test result (positive/negative)
- ✓Specific BRCA mutation identified (e.g., BRCA1 c.185delAG)
- ✓Family history of breast/ovarian cancer documented
- ✓Assessment of cancer risk based on BRCA mutation status
- ✓Management plan based on BRCA mutation and risk assessment
Common pitfalls to avoid
Coding BRCA mutation without definitive genetic test confirmation leads to inaccurate risk assessment and potential overtreatment.
Failing to specify BRCA1 or BRCA2 mutation when documented impacts personalized treatment strategies and surveillance recommendations.
Inconsistent coding of family history of breast/ovarian cancer alongside BRCA mutation affects risk stratification and preventive measures.
Best-practice tips
- 01Genetic counseling: Assess BRCA1/2 risk, family history.
- 02Prophylactic surgery: Mastectomy, salpingo-oophorectomy.
- 03Enhanced surveillance: MRI, mammogram, early/frequent.
- 04Chemoprevention: Tamoxifen, raloxifene, discuss options.
- 05Targeted therapy: PARP inhibitors for BRCA+ cancers.
Step-by-step checklist
- 1
Verify personal/family history of breast, ovarian, prostate, or pancreatic cancer
- 2
Review NCCN guidelines for BRCA testing criteria (e.g., age, ancestry)
- 3
Confirm patient understands genetic testing implications (pre/post)
- 4
Document ICD-10-CM code (e.g., Z15.01) and genetic test order details
Ready-to-paste narrative
Patient presents for genetic counseling and BRCA mutation testing due to family history of breast cancer and ovarian cancer. The patient reports a maternal aunt diagnosed with breast cancer at age 42 and a maternal grandmother diagnosed with ovarian cancer at age 55. No paternal family history of breast or ovarian cancer is reported. Patient denies personal history of breast lumps, nipple discharge, or skin changes. Physical exam reveals no palpable breast masses or lymphadenopathy. Genetic testing for BRCA1 and BRCA2 mutations was ordered to assess hereditary breast and ovarian cancer syndrome risk. Pre-test genetic counseling was provided, including discussion of potential results, implications for cancer risk management, and options for increased surveillance, prophylactic surgery, or chemoprevention. Informed consent was obtained. Results of genetic testing will be reviewed with the patient upon completion and appropriate referrals made for further management based on findings. Differential diagnoses include familial breast cancer, sporadic breast cancer, and other hereditary cancer syndromes. ICD-10 code Z13.82, Encounter for genetic susceptibility testing for malignant neoplasms of breast, is noted. CPT codes for genetic counseling and BRCA testing will be documented upon completion of services. This assessment supports the medical necessity of BRCA gene mutation analysis based on NCCN guidelines for hereditary breast and ovarian cancer syndrome.
Common questions and answers
What are the most current National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 mutation testing in patients with a family history of breast or ovarian cancer?+
The NCCN guidelines for BRCA1/2 mutation testing are regularly updated and represent best practice recommendations for identifying individuals at increased risk of hereditary breast and ovarian cancers. Current guidelines recommend BRCA1/2 testing for individuals with a personal or family history suggestive of hereditary breast and/or ovarian cancer syndrome, including early-onset breast cancer, bilateral breast cancer, triple-negative breast cancer diagnosed before age 60, ovarian cancer, male breast cancer, Ashkenazi Jewish ancestry with breast or ovarian cancer, or close relatives with known BRCA1/2 mutations. The specific criteria are complex and encompass various factors, including age of onset, tumor characteristics, and family history details. Clinicians should consult the latest NCCN guidelines for the most up-to-date recommendations to ensure appropriate patient selection for genetic testing and personalized risk management strategies. Explore how advancements in genetic testing technology are expanding access to testing and enabling more precise risk stratification. Consider implementing a standardized approach to family history assessment and BRCA testing within your practice to improve early detection and cancer prevention efforts.
How can I differentiate between the clinical presentation of BRCA1-associated breast cancer versus BRCA2-associated breast cancer to better inform treatment decisions?+
While both BRCA1 and BRCA2 mutations significantly increase the risk of breast cancer, there are some notable differences in the clinical presentation. BRCA1-associated breast cancers are more frequently triple-negative (lacking estrogen, progesterone, and HER2 receptors) and tend to occur at an earlier age. They are also often associated with a higher grade and more aggressive growth. BRCA2-associated breast cancers are more likely to be estrogen receptor-positive and present at a slightly later age. Understanding these distinct characteristics can inform treatment decisions, such as the selection of chemotherapy regimens and the potential role of PARP inhibitors. Learn more about the latest research on targeted therapies for BRCA-associated breast cancers to optimize patient outcomes and personalize treatment strategies based on the specific mutation.
What are the key considerations for genetic counseling and risk management for patients with a positive BRCA1 or BRCA2 mutation, including options for prophylactic surgery and chemoprevention?+
A positive BRCA1/2 mutation result has significant implications for a patient's health management and requires comprehensive genetic counseling. Counseling should address the patient's individual risk of developing breast and ovarian cancer, discuss risk-reducing strategies such as increased surveillance, prophylactic mastectomy and/or salpingo-oophorectomy, and chemoprevention options. The discussion should also include the psychological impact of a positive result and implications for family members. Shared decision-making is crucial, and the selected management strategy should be tailored to the patient's age, personal and family history, and individual preferences. Consider implementing a multidisciplinary approach involving oncologists, genetic counselors, and surgeons to provide comprehensive care for patients with BRCA mutations. Explore the resources available to support patients through the decision-making process and facilitate long-term risk management.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.